{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T10:36:25Z","timestamp":1769942185011,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014391","name":"Frankfurt University of Applied Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014391","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Trotz genereller Fortschritte bei der Hepatitis-C-Behandlung in Deutschland ist unklar, inwieweit dies auch f\u00fcr bestimmte Schl\u00fcsselgruppen, wie etwa Inhaftierte, gilt.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methoden<\/jats:title>\n                <jats:p>In einer Kurzbefragung im Juni 2021 wurden die Justizministerien der Bundesl\u00e4nder \u00fcber Datenerhebungs- und Diagnostikmethoden sowie die Pr\u00e4valenz von Infektionen mit dem Hepatitis-C-Virus (HCV) und HCV-Behandlungen von Gefangenen in Deutschland befragt. Erg\u00e4nzend dazu wurden Expert*inneninterviews zu Barrieren und bisher nicht genutzten Chancen der HCV-Behandlung in Haft gef\u00fchrt.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Es zeigt sich, dass keine vollst\u00e4ndige und fl\u00e4chendeckende Datenerhebung innerhalb der Justizministerien vorliegt. Pr\u00e4ventionsma\u00dfnahmen wie Opiatsubstitutionstherapie in Haft sind in allen teilnehmenden Bundesl\u00e4ndern verf\u00fcgbar. Spezifischere Angebote und Ma\u00dfnahmen (z.\u202fB. Rasierer, Spritzentausch) finden sich nur vereinzelt und sind teilweise kostenpflichtig. Die Expert*innen zeigen auf, dass die Behandlung innerhalb der Justizvollzugsanstalten zwar grunds\u00e4tzlich dem \u00c4quivalenzprinzip nachkommt, aber die Zielgruppe schwerer zu erreichen ist.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Fazit<\/jats:title>\n                <jats:p>Wichtig f\u00fcr eine erfolgreiche HCV-Eliminierung in Justizvollzugsanstalten sind eine fl\u00e4chendeckende Aufkl\u00e4rung und Beratung zur HCV-Behandlung, konsequente HCV-Testung und -Behandlung sowie Pr\u00e4ventionsma\u00dfnahmen zur Vermeidung von (Re)Infektionen.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00103-023-03808-y","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T18:01:35Z","timestamp":1703786495000},"page":"36-44","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hepatitis\u00a0C in Haftanstalten","Hepatitis\u00a0C in prisons"],"prefix":"10.1007","volume":"67","author":[{"given":"Anna","family":"Dichtl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Jamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heino","family":"St\u00f6ver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meryem","family":"Grabski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e4rbel","family":"Knorr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"issue":"2","key":"3808_CR1","first-page":"59","volume":"23","author":"H St\u00f6ver","year":"2021","unstructured":"St\u00f6ver\u00a0H, Keppler\u00a0K (2021) Opioidsubstitutionsbehandlung im Justizvollzug: Welche Belege f\u00fcr die Wirksamkeit, welche Hindernisse und welche L\u00f6sungsm\u00f6glichkeiten bestehen? Suchtmedizin 23(2):59\u201366","journal-title":"Suchtmedizin"},{"key":"3808_CR2","unstructured":"Robert Koch-Institut (2016) Abschlussbericht der Studie \u201eDrogen und chronische Infektionskrankheiten in Deutschland (DRUCK-Studie)\u201c"},{"key":"3808_CR3","unstructured":"Die Drogenbeauftragte, Bundesregierung (2019) Drogen- und Suchtbericht 2019"},{"issue":"1","key":"3808_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/epirev\/mxaa003","volume":"42","author":"B Moazen","year":"2020","unstructured":"Moazen\u00a0B, Dolan\u00a0K, Saeedi Moghaddam\u00a0S, Lotfizadeh\u00a0M, Duke\u00a0K, Neuhann\u00a0F et\u00a0al (2020) Availability, accessibility, and coverage of needle and syringe programs in prisons in the European Union. Epidemiol Rev 42(1):19\u201326","journal-title":"Epidemiol Rev"},{"key":"3808_CR5","series-title":"Disease","first-page":"100","volume-title":"History of detention and the risk of hepatitis\u00a0C among people who inject drugs in","author":"M Gassowski","year":"2019","unstructured":"Gassowski\u00a0M, Nielsen\u00a0S, Bannert\u00a0N, Bock\u00a0CT, Bremer\u00a0V, Ross\u00a0RS et\u00a0al (2019) History of detention and the risk of hepatitis\u00a0C among people who inject drugs in Germany. International Journal of Infectious Disease 81:100\u2013106"},{"issue":"48","key":"3808_CR6","first-page":"808","volume":"115","author":"A Opitz-Welke","year":"2018","unstructured":"Opitz-Welke\u00a0A, Lehmann\u00a0M, Seidel\u00a0P, Konrad\u00a0N (2018) Medizin im Justizvollzug. Dtsch \u00c4rztebl Int 115(48):808\u2013814","journal-title":"Dtsch \u00c4rztebl Int"},{"issue":"49","key":"3808_CR7","doi-asserted-by":"publisher","first-page":"2002093","DOI":"10.2807\/1560-7917.ES.2021.26.49.2002093","volume":"26","author":"L Wiessing","year":"2021","unstructured":"Wiessing\u00a0L, Kalamara\u00a0E, Stone\u00a0J, Altan\u00a0P, Van Baelen\u00a0L, Fotiou\u00a0A et\u00a0al (2021) Univariable associations between a\u00a0history of incarceration and HIV and HCV prevalence among people who inject drugs across 17\u00a0countries in Europe 2006 to 2020\u2014is the precautionary principle applicable? Euro Surveill 26(49):2002093","journal-title":"Euro Surveill"},{"key":"3808_CR8","volume-title":"Brief: consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations","author":"World Health Organization","year":"2017","unstructured":"World Health Organization (2017) Policy Brief: consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations"},{"issue":"1","key":"3808_CR9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1186\/s12889-017-4840-4","volume":"17","author":"J M\u00fcller","year":"2017","unstructured":"M\u00fcller\u00a0J, Schmidt\u00a0D, Kollan\u00a0C, Lehmann\u00a0M, Bremer\u00a0V, Zimmermann\u00a0R (2017) High variability of TB, HIV, hepatitis\u00a0C treatment and opioid substitution therapy among prisoners in Germany. Bmc Public Health 17(1):843","journal-title":"Bmc Public Health"},{"key":"3808_CR10","unstructured":"Assembly, U. G. (2015). UN General Assembly, Transforming Our World: The 2030 Agenda for Sustainable Development, 21\u00a0October 2015, A\/RES\/70\/1"},{"key":"3808_CR11","volume-title":"BIS 2030 \u2013 Strategie zur Eind\u00e4mmung von HIV, Hepatitis\u00a0B und\u00a0C und anderen sexuell \u00fcbertragbaren Infektionen","author":"Bundesministerium f\u00fcr Gesundheit\/Bundesministerium f\u00fcr wirtschaftliche Zusammenarbeit und Entwicklung","year":"2016","unstructured":"Bundesministerium f\u00fcr Gesundheit\/Bundesministerium f\u00fcr wirtschaftliche Zusammenarbeit und Entwicklung (2016) BIS 2030 \u2013 Strategie zur Eind\u00e4mmung von HIV, Hepatitis\u00a0B und\u00a0C und anderen sexuell \u00fcbertragbaren Infektionen"},{"issue":"07","key":"3808_CR12","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1055\/a-0599-1320","volume":"56","author":"C Sarrazin","year":"2018","unstructured":"Sarrazin\u00a0C, Zimmermann\u00a0T, Berg\u00a0T, Neumann\u00a0UP, Schirmacher\u00a0P, Schmidt\u00a0H et al (2018) S3-Leitlinie \u201eProphylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV)-Infektion\u201c. Z\u00a0Gastroenterol 56(07):756\u2013838","journal-title":"Z Gastroenterol"},{"issue":"1","key":"3808_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-230X-14-87","volume":"14","author":"MH Wehmeyer","year":"2014","unstructured":"Wehmeyer\u00a0MH, Ei\u00dfing\u00a0F, Jordan\u00a0S, R\u00f6der\u00a0C, Hennigs\u00a0A, Degen\u00a0O et al (2014) Safety and efficacy of protease inhibitor based combination therapy in a\u00a0single-center \u201creal-life\u201d cohort of 110 patients with chronic hepatitis\u00a0C genotype 1 infection. BMC Gastroenterol 14(1):1\u201310","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"3808_CR14","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/apt.14592","volume":"47","author":"J Von Felden","year":"2018","unstructured":"Von Felden\u00a0J, Vermehren\u00a0J, Ingiliz\u00a0P, Mauss\u00a0S, Lutz\u00a0T, Simon\u00a0K et al (2018) High efficacy of sofosbuvir\/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis\u00a0C genotype 3 infection. Aliment Pharmacol Ther 47(9):1288\u20131295","journal-title":"Aliment Pharmacol Ther"},{"issue":"05","key":"3808_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1055\/a-1852-5713","volume":"61","author":"K Kr\u00fcger","year":"2023","unstructured":"Kr\u00fcger\u00a0K, Rossol\u00a0S, Krauth\u00a0C, Buggisch\u00a0P, Mauss\u00a0S, Stoehr\u00a0A et al (2023) Real-world experience for the outcomes and costs of treating hepatitis\u00a0C patients: Results from the German Hepatitis\u00a0C-Registry (DHC-R). Z\u00a0Gastroenterol 61(05):489\u2013503","journal-title":"Z Gastroenterol"},{"issue":"2","key":"3808_CR16","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1002\/hsr2.290","volume":"4","author":"C Sarrazin","year":"2021","unstructured":"Sarrazin\u00a0C, Boesecke\u00a0C, Golsabahi-Broclawski\u00a0S, Moog\u00a0G, Negro\u00a0F, Silaidos\u00a0C et al (2021) Hepatitis\u00a0C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal. Health Sci Reports 4(2):e290","journal-title":"Health Sci Reports"},{"issue":"7","key":"3808_CR17","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/jvh.13680","volume":"29","author":"TL Tergast","year":"2022","unstructured":"Tergast\u00a0TL, Blach\u00a0S, Tacke\u00a0F, Berg\u00a0T, Cornberg\u00a0M, Kautz\u00a0A et\u00a0al (2022) Updated epidemiology of hepatitis\u00a0C virus infections and implications for hepatitis\u00a0C virus elimination in Germany. J\u00a0Viral Hepat 29(7):536\u2013542","journal-title":"J Viral Hepat"},{"issue":"2","key":"3808_CR18","first-page":"159","volume":"1","author":"P Mayring","year":"2004","unstructured":"Mayring\u00a0P (2004) Qualitative content analysis. A\u00a0Companion To Qual Res 1(2):159\u2013176","journal-title":"A Companion To Qual Res"},{"key":"3808_CR19","first-page":"76","volume-title":"Gef\u00e4ngnismedizin","author":"BD Meier","year":"2009","unstructured":"Meier\u00a0BD (2009) 4.1 \u00c4quivalenzprinzip. In: Keppler\u00a0K, St\u00f6ver\u00a0H, Keppler\u00a0K, St\u00f6ver\u00a0H (Hrsg) Gef\u00e4ngnismedizin. Thieme, Stuttgart, S\u00a076\u201384"},{"key":"3808_CR20","doi-asserted-by":"crossref","unstructured":"Buggisch P, Heiken H, Mauss S, Weber B, Jung MC, G\u00f6rne H et al (2020) Barrieren der Hepatitis-C-Virus (HCV) Elimination in Deutschland: warum erhalten diagnostizierte Patienten keine Therapie? Z\u00a0Gastroenterol","DOI":"10.1055\/s-0040-1716161"},{"issue":"5","key":"3808_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S2468-1253(20)30365-4","volume":"6","author":"MJ Akiyama","year":"2021","unstructured":"Akiyama\u00a0MJ, Kronfli\u00a0N, Cabezas\u00a0J, Sheehan\u00a0Y, Thurairajah\u00a0PH, Lines\u00a0R et\u00a0al (2021) Hepatitis\u00a0C elimination among people incarcerated in prisons: challenges and recommendations for action within a\u00a0health systems framework. Lancet Gastroenterol Hepatol 6(5):391\u2013400","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3808_CR22","doi-asserted-by":"crossref","unstructured":"Winter RJ, Sheehan Y, Papaluca T, Macdonald GA, Rowland J, Colman A et\u00a0al (2023) Consensus recommendations on the management of hepatitis\u00a0C in Australia\u2019s prisons. Med J Aust","DOI":"10.5694\/mja2.51854"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-023-03808-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00103-023-03808-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-023-03808-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T11:05:38Z","timestamp":1704798338000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00103-023-03808-y"}},"subtitle":["Behandlung und Barrieren auf dem Weg zu den Eliminierungszielen der Vereinten Nationen","Treatment and barriers to the elimination goals of the United Nations"],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["3808"],"URL":"https:\/\/doi.org\/10.1007\/s00103-023-03808-y","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,28]]},"assertion":[{"value":"20 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Dichtl, D.\u00a0Jamin, H.\u00a0St\u00f6ver, M.\u00a0Grabski und B.\u00a0Knorr geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}